New technologies for next-gen antibody therapeutics

AAX Biotech is a research-driven biotech company with proprietary technologies that solve unmet needs in the development of next-generation antibody therapeutics. The company’s two unique and patentable technologies improve the performance and developability of antibody-based therapeutics.

With the Seqitope™ technology, drug developers can accelerate drug development by resolving in detail epitope-binding properties at an early stage. The second technology – Opti-mAb™ – is a molecular stabilization strategy for scFv antibodies, providing significantly more stable, non-aggregating and therefore cost-effective drug development and improved pharmacological properties.

AAX Biotech is the winner of the AbbVie Scandinavia Golden Ticket, launched in collaboration with SmiLe, thereby receiving a membership in SmiLe’s incubator program.